Medicine, Antibiotics Exports Gaining Share In US, Italian Markets: Govt Data According To The Commerce Ministry Data, India

New Delhi: With the Union government focusing on boosting domestic manufacturing of pharmaceutical products, India’s medicine and antibiotics exports have started gaining significant market share in the US.

According to the commerce ministry data, India is the third largest import source of ‘medicine put up for retail sale’ for the US. The top two are Ireland and Switzerland.

In 2023, the country exported these medicines worth $9 billion as against $7.33 billion in 2022.

With this increase in the shipments, India’s share went up to 13.1 percent in 2023 from 10.08 percent in 2022. Share of the top exporter Ireland fell to 13.85 percent in 2023 from 17.18 percent in 2022 because its sales in the US went down to $9.5 billion in 2023 from $12.5 billion in 2022.

The second biggest exporter Switzerland also saw its share decline to 13.7 percent last year from 17.4 percent in 2022.

Similarly, India has increased its share among exporters of antibiotics in the Italian market. It is ranked 10th in that market by increasing its share to 2.12 percent in 2023 from 0.96 percent in 2022.

In value terms, the country’s antibiotics exports to Italy stood at $23.34 million in 2023 as against $11.48 million in 2022.

Further, the data showed that India’s competitiveness is growing in the Magnetic Resonance Imaging (MRI) apparatus market of Germany.

In 2023, the country made a small gain by increasing its export share in Germany to 1.7 percent from 0.45 per cent in 2022.

In value terms, India exported these MRI machines worth $13.02 million last year as against $2.93 million in 2022.

India is the sixth largest exporter of MRI apparatus, whereas the UK is the leader with exports of $460 million.

“Penetrating the EU market is difficult and it is important that we have a base coming in. These reflect some efforts which are being put in terms of monitoring various markets and various commodities to see where growth can be pushed,” an official said.

Pharma and medical devices manufacturing is the priority area for the government and these two sectors were the first ones to get a Production Linked Incentive (PLI) scheme.

Related Posts

Telangana official urges pharma sector to treat safety as a competitive edge, not a checkbox

Sarvesh Singh, Director and CEO of Telangana Lifesciences and Pharma, called on industry leaders at a CII Telangana conference to embed safety by design into manufacturing culture, deploying AI, IoT,…

CDSCO Approves Indian Pharma Companies for EU API Exports, Opening New Growth Opportunities

Amidst tariff tensions with the US, Europe has created a major opportunity for the Indian pharmaceutical industry. The CDSCO has granted approval to three Indian companies to export APIs to…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Telangana official urges pharma sector to treat safety as a competitive edge, not a checkbox

Telangana official urges pharma sector to treat safety as a competitive edge, not a checkbox

CDSCO Approves Indian Pharma Companies for EU API Exports, Opening New Growth Opportunities

CDSCO Approves Indian Pharma Companies for EU API Exports, Opening New Growth Opportunities

Four booked for cheating pharma firm manager of ₹26 lakh with promise of PDO job

Four booked for cheating pharma firm manager of ₹26 lakh with promise of PDO job

Puducherry drugs inspector suspended after counterfeit medicine crackdown

Puducherry drugs inspector suspended after counterfeit medicine crackdown

Researchers discover a compound that can boost ageing muscle repair

Researchers discover a compound that can boost ageing muscle repair

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks